Drug intelligence / Profile preview

New Wumeiwan Formula

Development stage: Preclinical
Lead developer: Beijing University of Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

New Wumeiwan Formula is an investigational traditional Chinese medicine (TCM) herbal formula developed by Beijing University of Chinese Medicine (specifically Dongfang Hospital) and Peking University First Hospital for the treatment of severe active ulcerative colitis. Based on the classic 'Wumeiwan' (Black Plum Pill) formula from the *Treatise on Cold Damage Diseases* (Shanghan Lun), this modified formulation is designed to clear heat, resolve dampness, detoxify, resolve stasis, warm the kidney, and strengthen the spleen. It is composed of herbs including *Fructus Mume* (Wumei), *Rhizoma Zingiberis Praeparatum* (Paojiang), *Radix Aconiti Lateralis Praeparata* (Fuzi), *Rhizoma Coptidis* (Huanglian), and *Radix Scutellariae Carbonisata* (Huangqintan). In clinical trials, it is evaluated in combination with prednisone and/or mesalazine to assess its efficacy and safety in patients with severe active ulcerative colitis.

Other names: New Wumei pillXin Wu Mei WanXin Wumeiwan Formula新乌梅丸新乌梅丸方新乌梅丸颗粒

Targets

MAPK12 (Mitogen-activated protein kinase 12)RIPK3STAT6 (Signal Transducer and Activator of Transcription 6)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on New Wumeiwan Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Wumeiwan Formula.

Explore the full profile